Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19383922)

  • 1. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SRC in mucinous ovarian carcinoma.
    Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
    Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
    Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
    Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
    Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
    Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
    Nautiyal J; Banerjee S; Kanwar SS; Yu Y; Patel BB; Sarkar FH; Majumdar AP
    Int J Cancer; 2011 Feb; 128(4):951-61. PubMed ID: 20473900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
    Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
    Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
    Strickler JH; McCall S; Nixon AB; Brady JC; Pang H; Rushing C; Cohn A; Starodub A; Arrowood C; Haley S; Meadows KL; Morse MA; Uronis HE; Blobe GC; Hsu SD; Zafar SY; Hurwitz HI
    Invest New Drugs; 2014 Apr; 32(2):330-9. PubMed ID: 24173967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
    Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
    Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
    Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
    J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
    Dai Y; Chen S; Shah R; Pei XY; Wang L; Almenara JA; Kramer LB; Dent P; Grant S
    Blood; 2011 Feb; 117(6):1947-57. PubMed ID: 21148814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
    Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
    J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
    Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
    Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
    Premkumar DR; Jane EP; Pollack IF
    Int J Oncol; 2010 Sep; 37(3):633-43. PubMed ID: 20664932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.